Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read more on ACAD stock here.
In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately ...
Min Son of Hanol IP & Law explains how a ruling has rejected attempts to limit protection to initially approved drug ...
President Donald Trump has a new opportunity to secure intellectual property victories in the upcoming U.S.-Mexico-Canada ...
Figuring out the best iPad for you can be a little tricky. Apple now sells three different 11-inch tablets and two 13-inch models, each with key differences in pricing, specs and accessory support.
Objectives To review the metrics and findings of studies evaluating effects of drug decriminalisation or legal regulation on drug availability, use or related health and social harms globally. Design ...
ZDNET experts put every product through rigorous testing and research to curate the best options for you. If you buy through our links, we may earn a commission. Learn Our Process 'ZDNET Recommends': ...
HonorTech's latest mobile launch is the Honor Pad X8a. The tablet was launched in September 2024. The tablet comes with a 11.00-inch touchscreen display with a resolution of 1920 pixels by 1200 pixels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback